Home/Filings/4/0001209191-20-039976
4//SEC Filing

LARANJEIRA CHARLES ANTHONY 4

Accession 0001209191-20-039976

CIK 0001396814other

Filed

Jun 30, 8:00 PM ET

Accepted

Jul 1, 9:17 PM ET

Size

25.0 KB

Accession

0001209191-20-039976

Insider Transaction Report

Form 4
Period: 2020-06-29
LARANJEIRA CHARLES ANTHONY
SVP, Technical Operations
Transactions
  • Sale

    Common Stock

    2020-06-29$50.01/sh51,464$2,573,71528,887 total
  • Sale

    Common Stock

    2020-06-29$51.77/sh6,859$355,09022,028 total
  • Exercise/Conversion

    Common Stock

    2020-06-29$37.81/sh+3,750$141,78827,851 total
  • Exercise/Conversion

    Common Stock

    2020-06-29$43.54/sh+7,500$326,55050,351 total
  • Exercise/Conversion

    Common Stock

    2020-06-29$44.10/sh+30,000$1,323,00080,351 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2020-06-293,7506,250 total
    Exercise: $37.81Exp: 2029-01-03Common Stock (3,750 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2020-06-2915,00015,000 total
    Exercise: $38.35Exp: 2028-06-13Common Stock (15,000 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2020-06-297,50022,500 total
    Exercise: $43.54Exp: 2029-06-05Common Stock (7,500 underlying)
  • Exercise/Conversion

    Common Stock

    2020-06-29$38.35/sh+15,000$575,25042,851 total
  • Sale

    Common Stock

    2020-06-29$52.03/sh1,778$92,50920,250 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2020-06-2930,00010,000 total
    Exercise: $44.10Exp: 2027-06-02Common Stock (30,000 underlying)
Footnotes (6)
  • [F1]The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.94, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2, 3 and 4.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.06 to $51.99, inclusive.
  • [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.00 to $52.10, inclusive.
  • [F5]The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.
  • [F6]The stock option vests and becomes exercisable as to 25% of the option shares on May 1, 2018, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

Issuer

Pacira BioSciences, Inc.

CIK 0001396814

Entity typeother

Related Parties

1
  • filerCIK 0001524338

Filing Metadata

Form type
4
Filed
Jun 30, 8:00 PM ET
Accepted
Jul 1, 9:17 PM ET
Size
25.0 KB